Marshall Wace
KRSA icon

Marshall Wace’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Marshall Wace’s Portfolio KRSA Stock Details KRSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.21M Buy
+131,552
New +$3.65M ﹤0.01% 1435
2022
Q1 		– Sell
-75
Closed -$18K – 3463
2021
Q4 		$18K Buy
+75
New +$24.8K ﹤0.01% 3713
2021
Q3 		– Sell
-206
Closed -$113K – 3080
2021
Q2 		$113K Buy
+206
New +$90.3K ﹤0.01% 2529

Other funds holding KRSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
General Atlantic
General Atlantic New York $2.48B AUM 19.88% 1-Year Est. Return
Vivo Capital
Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return
Remedium Capital Partners
Remedium Capital Partners Fort Lauderdale, Florida $274M AUM 288.41% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $132M AUM 92.09% 1-Year Est. Return
Spruce Street Capital
Spruce Street Capital New York $629M AUM 210.46% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return
NEXTBio Capital Management
NEXTBio Capital Management Menlo Park, California $234M AUM 176.49% 1-Year Est. Return

Marshall Wace's KRSA Position: Q3 2026 in Review

Marshall Wace opened a new position in Korsana Biosciences, Inc. Common Stock (KRSA) in Q3 2026: 131,552 shares worth $4.21M. The stake represents ﹤0.01% of the portfolio and ranks #1435 among its holdings. This is a return to the name: Marshall Wace previously reported a position in KRSA as recently as Q4 2021.

Marshall Wace first reported a position in KRSA in Q2 2021 and has held it in 3 quarters since. 24 funds tracked by Wall St. Rank hold KRSA as of Q3 2026.

  • Marshall Wace held 131,552 shares of Korsana Biosciences, Inc. Common Stock worth $4.21M as of Q3 2026.
  • Korsana Biosciences, Inc. Common Stock was a new Marshall Wace position in Q3 2026.
  • Korsana Biosciences, Inc. Common Stock made up ﹤0.01% of Marshall Wace's portfolio in Q3 2026, its #1435 holding.
  • Marshall Wace first reported a position in Korsana Biosciences, Inc. Common Stock in Q2 2021 and has held it in 3 quarters since.
  • 24 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q3 2026.

Based on Marshall Wace's 13F filing for Q3 2026, filed 13 Nov 2026.